Alembic Pharmaceuticals Limited — Credit Ratings, 12-06-2025: Credit Rating

Crisil Ratings has reaffirmed Alembic Pharmaceuticals Limited’s commercial paper rating at CRISIL A1+ and increased the limit from Rs. 750 Cr to Rs. 1,100 Cr. This top-tier rating reflects strong confidence in the company’s timely debt servicing and solid liquidity management. The higher limit enhances Alembic's flexibility to manage short-term funding needs efficiently, which could help in lowering its borrowing costs and strengthen investor trust. The reaffirmation underscores the company’s stable credit profile and prudent financial discipline.